Links
Employee opinions on their health insurance. Republican vs. Democratic physicians. States’ perspective on private equity in health care. California’s expansion of Medi-Cal for Unauthorized Residents. 4D geometry.
Month: November 2024
Battle Royale: Small molecules vs. biologics
The Inflation Reduction Act (IRA) allows the Centers for Medicare and Medicaid Services to negotiate drug prices. However, CMS can only negotiated drug prices 9 years after drug approval for small molecules and 13 years after approval for large molecules. Why the difference? Do biologic treatments produce superior health benefits for patients? This is the…
How does competition impact community health center quality of care?
That is the question posted by a recent paper by Li and Dor (2024). However, they define competition not just by the number of community health center (CHC) competitors or market concentration (e.g., Herfindahl-Hirschman Index, HHI) but also the quality of care provided by their competitors. A key methodological question is how this should be…
A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria
That is the title of my recent paper with co-authors Denise Clayton, Glorian Yen, Lincy Geevarghese, Yulin Shi Anem Waheed. The abstract is below. IntroductionParoxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease associated with complications that increase morbidity, such as thrombosis and chronic kidney disease. Limited data exist regarding complications among treated patients outside…
Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses?
Cost effectiveness analyses (CEA) aim to examine how a new health technologies impact health outcomes and costs over a patient’s lifetime. While extrapolating long-run health benefits and measuring potential cost offsets are important, another important item to estimate is how the cost of the new health technology is likely to evolve over times. This is…